Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose <sup>211</sup>At-Labeled Anti-HER2 Single-Domain Antibody Fragment.

Feng, Yutian; Meshaw, Rebecca; Zhao, Xiao-Guang; Jannetti, Stephen; Vaidyanathan, Ganesan; Zalutsky, Michael R

Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose ²¹¹At-Labeled Anti-HER2 Single-Domain Antibody Fragment.

Feng, Yutian; Meshaw, Rebecca; Zhao, Xiao-Guang; Jannetti, Stephen; Vaidyanathan, Ganesan; Zalutsky, Michael R.

Afiliación

Feng Y; Department of Radiology, Duke University Medical Center, Durham, North Carolina.
Meshaw R; Department of Radiology, Duke University Medical Center, Durham, North Carolina.
Zhao XG; Department of Radiology, Duke University Medical Center, Durham, North Carolina.
Jannetti S; Department of Radiology, Duke University Medical Center, Durham, North Carolina.
Vaidyanathan G; Department of Radiology, Duke University Medical Center, Durham, North Carolina.
Zalutsky MR; Department of Radiology, Duke University Medical Center, Durham, North Carolina zalut001@mc.duke.edu.

J Nucl Med ; 64(1): 124-130, 2023 01.

Article en En | MEDLINE | ID: mdl-35618478

Asunto(s)

Neoplasias de la Mama; Anticuerpos de Dominio Único; Humanos; Animales; Ratones; Femenino; Anticuerpos de Dominio Único/uso terapéutico; Anticuerpos de Dominio Único/metabolismo; Xenoinjertos; Receptor ErbB-2/metabolismo; Neoplasias de la Mama/radioterapia; Neoplasias de la Mama/metabolismo; Línea Celular Tumoral; Resultado del Tratamiento

Palabras clave

211At; HER2; nanobody; radiopharmaceutical therapy; single-domain antibody fragment; α-emitter

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Anticuerpos de Dominio Único Límite: Animals / Female / Humans Idioma: En Revista: J Nucl Med Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google